Abstract 477P
Background
Lower grade gliomas (LGGs) represent 15% of all primary brain tumors, and have variable prognosis. The prognostic influence of the ENHO gene in LGGs remains elusive, necessitating further bioinformatic exploration to improve patient management and outcomes.
Methods
Differential gene expression based on High/low ENHO expression was extracted using the “DESeq2” R package. Immune infiltration, mutational burden, gene set variation analysis (GSVA) and drug resistance were analyzed through GSCALite and cBioPortal. Additional immune infiltration and survival analysis used TIMER2.0. Gene set enrichment analysis (GSEA) was conducted via TCGAbiolinks and enriched further using Enrichr.
Results
Multivariate overall survival (OS) analysis showed a protective effect for ENHO (HR = 0.58, p <0.001). GSVA for OS and progression-free survival (PFS) for co-expressed genes and upregulated genes also showcased favorable prognosis OS:(HR = 0.40, p<0.001) and (HR = 0.34, p<0.001), respectively; PFS: (HR = 0.53, p<0.001) and (HR = 0.44, p<0.001), respectively. Survival GSVA of downregulated genes revealed an association with worse OS (HR = 4.19, p < 0.001) and PFS (HR = 2.45, p< 0.001). GSVA for upregulated genes showed a negative correlation with DNA damage, EMT, and PI3KAKT pathways. GSVA for downregulated genes had a positive correlation with EMT, DNA damage, and PI3K/AKT pathways. GSVA for co-expressed genes revealed significant negative correlations with DNA damage and EMT pathways. Mutational burden analysis revealed that shallow deletion is the most common ENHO mutation among all LGG subtypes, regardless of stage. Immune infiltration analysis for ENHO, upregulated, and co-expressed genes showcased the infiltration of: Central memory B cells, CD8 T cells, Neutrophils, and CD4 T cells. Decreased infiltration of cancer associated fibroblasts was observed for high ENHO expression. GSEA of coexpressed genes revealed significant involvement in cell cycle processes and regulation.
Conclusions
ENHO's role in LGG is yet to be determined, but our results showcase a possible protective effect through its modulation of the immune system, cell cycle signalling, and EMT pathways. Primary studies are still needed to validate ENHO's role in LGG.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
457P - Progression-free survival 2 (PFS2) as a surrogate for overall survival in a multicentric real-world data cohort of glioblastoma (GBM)
Presenter: Jesus Yaringaño Cerna
Session: Poster session 16
458P - Patterns of care and clinical outcomes of patients with glioblastoma in the United States from 2005-2020: A real-world analysis
Presenter: Diya Jayram
Session: Poster session 16
459P - Association of tumor treating fields device usage with survival in newly diagnosed GBM: A real-world analysis of patients in the US
Presenter: Jennifer Connelly
Session: Poster session 16
460P - Exploring the efficacy and optimal timing of tumor treating fields in newly diagnosed glioblastoma: A real-world study
Presenter: Zelei Dai
Session: Poster session 16
461P - Effectiveness of dabrafenib-trametinib and larotrectinib in adult recurrent glioblastoma patients: A real-life cohort analysis from 3 Italian centers
Presenter: Marta Padovan
Session: Poster session 16
462P - Regorafenib for relapsed glioblastoma: Retrospective real-world analysis of a single Institution experience
Presenter: Giulia Rovesti
Session: Poster session 16
463P - Real-world outcomes of patients with non-small cell lung cancer with and without intracranial metastatic disease: A retrospective cohort analysis
Presenter: Madison Sherman
Session: Poster session 16
465P - Surgical intervention association with the development of subsequent dissemination in childhood diffuse intrinsic pontine gliomas (DIPG)
Presenter: Shoaib Bashir
Session: Poster session 16
Resources:
Abstract
466P - Re-irradiation therapy for pediatric brainstem tumours: 20 years of clinical experience
Presenter: Olga Regentova
Session: Poster session 16
Resources:
Abstract
467P - Temozolomide potentially postpones the development of subsequent metastases in pediatric diffuse intrinsic pontine glioma (DIPG) patients
Presenter: Shoaib Bashir
Session: Poster session 16
Resources:
Abstract